Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
October 2025
Secukinumab in active lupus nephritis: Results from Phase III, randomised, placebo controlled study (SELUNE) and open-label extension study
Rheumatology 2025 Doi: 10.1093/rheumatology/keaf536 Epub ahead of print
Secukinumab did not demonstrate superior efficacy over PBO in patients with active LN; secukinumab was well-tolerated with no new or unexpected safety signals detected. A Phase-III core study (SELUNE) and an extension study, were conducted by Zhao et al. to evaluate the efficacy and safety of SC secukinumab 300mg compared with PBO, in combination with the SoC, in patients with active LN.
Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature
Autoimmun Rev. 2022 doi: 10.1016/j.autrev.2022.103188
Gomez, et al. summarise the effects of biological therapies on SLE patients' health-related quality of life (HRQoL) in RCT and real-life settings, based on a systematic search of the literature.